Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Survival in adult inpatients with COVID-19

E. Murillo-Zamora a, b, C.M. Hernandez-Suarez c, *

a Departamento de Epidemiología, Unidad de Medicina Familiar No. 19, Instituto Mexicano del Seguro Social, Av. Javier Mina 301, Col. Centro, C.P. 28000, Colima, Colima, México
b Facultad de Medicina, Universidad de Colima, Av. Universidad 333, Col. Las Víboras, C.P. 28040, Colima, Colima, México
c Facultad de Ciencias, Universidad de Colima, Bernal Díaz del Castillo 340, Col. Villas San Sebastián, C.P. 28045, México

ABSTRACT

Background: The mortality of the coronavirus disease 2019 (COVID-19) pandemic is high, and data regarding its prognosis are scarce. We aimed to assess the survival experience and determining factors in adult inpatients with laboratory-confirmed COVID-19.

Methods: We conducted a nationwide and retrospective cohort study. Data from 66,123 individuals were analyzed using the Kaplan-Meier method, and a multivariate Cox proportional hazard regression model was fitted.

Results: The 7-day survival was 72.2% and went to 47.6%, 35.0%, and 23.9% on days 15, 21, and 30 of hospital stay, respectively. In the multiple analysis, factors associated with an increased risk of dying were male gender, age, pneumonia at hospital admission, immunosuppression, and personal history of chronic non-communicable diseases. Reduced risk of a fatal outcome was observed among patients with asthma history.

Conclusions: To the best of our knowledge, this is the largest study analyzing the survival probability in a large subset of Latin-American adults with COVID-19, in whom the disease burden has been high. Our results contribute to achieving a better understanding of disease evolution.

© 2020 The Royal Society for Public Health. Published by Elsevier Ltd. All rights reserved.

Background

Worldwide, the coronavirus disease 2019 (COVID-19) by severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) pandemic represents unprecedented health and social crisis. The clinical spectrum of SARS-COV-2 infection is wide and includes asymptomatic contagion, mild upper and unspecified respiratory tract symptoms, and severe viral pneumonia.1

The observed COVID-19 burden in Mexico has been high and, by the end of the first week of October 2020, more than 80 thousand deaths had been registered.2 In accordance with normative standards that have been followed since the beginning of the pandemic, hospitalization criteria include the use of validated scales as Pneumonia Severity Index and confusion, urea level, respiratory rate, blood pressure, and age > 65.3

Published data regarding the clinical course of COVID-19 inpatients are scarce, particularly in Latin-American populations.4

The evaluation of clinical outcomes in hospitalized patients with symptomatic SARS-COV-2 infection may help clinicians and epidemiologists better appreciate the disease evolution, and lead to a more efficient allocation of healthcare resources.4 This study aimed to assess the survival experience and associated factors in a large cohort of hospitalized adult inpatients with laboratory-confirmed COVID-19.

Methods

We conducted a nationwide and retrospective dynamic cohort study focusing on the survival of hospitalized adult patients with laboratory-confirmed (reverse transcription-polymerase chain reaction in nasopharyngeal and deep nasal swabs) COVID-19. Eligible subjects were identified from the nominal records of a normative and web-based system for the epidemiological surveillance of viral respiratory diseases, which belongs to the Mexican Institute of Social Security (IMSS, the Spanish acronym). A broader description of study methods was previously published.5

Individuals aged 18 years or older at acute illness onset and with conclusive evidence of COVID-19 by SARS-COV-2 were potentially
Results
de of hospitalized adult patients with COVID-19 measured as the time
and death certiﬁed in the audited database, which primary data sources are medical
2020, were excluded, as well as those with missing clinical or
eligible. Subjects with hospital admission date later than August 15,
Clinical and epidemiological data of interest were collected from
The Kaplan-Meier curve is presented in Supplementary Fig. 1.
HR, hazard ratio; CI, conﬁdence interval; BMI, body mass index; COVID-19, coronavirus disease 2019.
Notes: 1 Cox proportional hazard regression models were used to compute HR and 95% CI; 2) HR and 95% CI from multiple analysis were adjusted by variables listed in the
a) Self-reported household contact with a laboratory-confirmed case of COVID-19 within 14 days before symptoms onset.
b) Included any cause of immunosuppression except for type 2 diabetes mellitus or chronic kidney disease.

| Characteristic | Bivariate analysis | Multiple analysis |
|----------------|-------------------|-------------------|
| **Gender**     |                   |                   |
| Female         | 1.00              | 1.00              |
| Male           | 1.11 (1.08–1.13)  | <0.001            |
| **Age group (years)** |           |                   |
| 20 - 29        | 1.00              | 1.00              |
| 30 - 44        | 1.64 (1.47–1.83)  | 1.60 (1.44–1.79)  | <0.001 |
| 45 - 59        | 2.52 (2.27–2.80)  | 2.37 (2.13–2.63)  | <0.001 |
| 60+            | 3.92 (3.54–4.34)  | <0.001            | <0.001 |
| **Clinically diagnosed pneumonia at hospital admission** |                   |                   |
| No             | 1.00              | 1.00              |
| Yes            | 1.48 (1.45–1.51)  | <0.001            | <0.001 |
| **Personal history of** |                   |                   |
| Tobacco use    |                   |                   |
| No             | 1.00              | 1.00              |
| Yes            | 1.08 (1.04–1.12)  | <0.001            | 0.97 (0.93–1.01) | 0.115 |
| Obesity (BMI 30 or above) |           |                   |
| No             | 1.00              | 1.00              |
| Yes            | 1.01 (0.99–1.04)  | 0.306             | 1.08 (1.05–1.11) | <0.001 |
| Asthma         |                   |                   |
| No             | 1.00              | 1.00              |
| Yes            | 0.86 (0.80–0.93)  | <0.001            | 0.92 (0.85–0.99) | 0.037 |
| **Chronic pulmonary obstructive disease** |                   |                   |
| No             | 1.00              | 1.00              |
| Yes            | 1.41 (1.34–1.48)  | <0.001            | 1.12 (1.07–1.18) | <0.001 |
| **Type 2 diabetes mellitus** |           |                   |
| No             | 1.00              | 1.00              |
| Yes            | 1.30 (1.27–1.33)  | <0.001            | 1.09 (1.07–1.12) | <0.001 |
| **Arterial hypertension** |           |                   |
| No             | 1.00              | 1.00              |
| Yes            | 1.36 (1.33–1.39)  | <0.001            | 1.08 (1.05–1.11) | <0.001 |
| **Immunosuppression** |           |                   |
| No             | 1.00              | 1.00              |
| Yes            | 1.13 (1.06–1.21)  | <0.001            | 1.08 (1.01–1.16) | 0.021 |
| **Chronic kidney disease** |           |                   |
| No             | 1.00              | 1.00              |
| Yes            | 1.46 (1.41–1.52)  | <0.001            | 1.36 (1.31–1.42) | <0.001 |

The survival probabilities (and 95% CI) of COVID-19 adult inpatients at different days from hospital admission were as following: 1, 95.5% (95.3%–95.7%); 3, 86.9% (86.6%–87.2%); 7, 72.2% (71.9%–72.6%); 15, 47.6% (47.1%–48.1%); 21, 35.0% (34.4%–35.5%); and 30, 23.9% (23.3%–24.5%).

In the multiple model (Table 1), a personal history of asthma (HR = 0.92, 95% CI: 0.85–0.99) showed a protective effect on dying. All other evaluated exposures (namely: male gender, increasing age, clinical pneumonia at hospital entry, and personal history of obesity, immunosuppression, and other chronic non-communicable diseases [type 2 diabetes mellitus, arterial hypertension, and renal disease]) were associated with an increased risk for a fatal outcome. The highest risk increase (HR = 1.41%, 95% CI: 1.38–1.4) on dying was documented among patients with clinically diagnosed pneumonia at hospital admission.
Discussion

The results of this study describe the survival experience of hospitalized adults with COVID-19, and factors associated with disease outcomes were characterized. To the best of our knowledge, this is the largest study evaluating illness outcomes in a large subset of Latin-American COVID-19 inpatients.

The related burden of SARS-COV-2 in Mexico has been high and obesity and chronic non-communicable diseases (mainly type 2 diabetes mellitus), both of them showing epidemic characteristics in Mexican adults, may play a role in the observed scenario. The prevalence of type 2 diabetes mellitus and arterial hypertension in our study sample was significantly higher than national means (diabetes, 33.0% vs. 10.3%; hypertension, 40.4% vs. 18.4%; $P < 0.001$). These findings were secondary to the inclusion of cases requiring hospitalization because the personal history of chronic illness has been associated with a greater risk of severe COVID-19 manifestations and hospital entry.

Our survival estimates are a bit higher than those recently documented in Brazil, where the 15-day rate was around 40% (vs. 47.6% from our analysis). According to the authors from the cited Brazilian study, the lack of standardized protocols for clinical management of COVID-19 inpatients may be determining, at least partially, the observed scenario. The computed 14-day survival rate in a study that took place in the city of New York (U.S.), and where 2773 inpatients were analyzed, was around 50%, and it is 5% higher than ours. Demographic characteristics and country-specific control policies may have contributed, at least partially, to these observed differences.

The inclusion of only laboratory-positive cases, together with the large sample size and national representativeness, are major strengths of this study. However, potential limitations must be cited. First, we were unable to assess a gradient between body mass and survival functions because anthropometric registers are not collected by the audited epidemiological surveillance system. Instead, obesity data are collected as a dichotomous variable. And second, no biomarkers data were available and which may have improved the accuracy of built models.

Conclusions

The COVID-19 pandemic-related mortality in Latin-America has been high. The survival experience of hospitalized adults in Mexico was documented in this nationwide study, and factors determining the illness outcome were assessed. Because obesity and other related chronic non-communicable diseases such type 2 diabetes mellitus and arterial hypertension were associated with a poorer prognosis, our results highlight the major relevance of public health policies and interventions focusing on their prevention in the analyzed population.

Author statements

Ethical approval

None sought.

Funding

None declared.

Competing interests

None to declare.

Data availability statement

The data that support the findings of this study are available on request to the corresponding author.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.puhe.2020.10.029.

References

1. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395 (10229): 1054–62.
2. Wolff R, Corman VM, Guggemos W, Snijders E, Zange S, Muller MA, et al. Virological assessment of hospitalized patients with COVID-19. Nature 2020; 581(7809): 465–9.
3. Government of Mexico and Health Ministry. Clinical guidelines for the attention of COVID-19 patients. Available at: https://doi.org/10.1016/j.puhe.2020.10.029.
4. Liang WH, Guan WJ, Li CC, Li YM, Liang HR, Zhao Y, et al. Clinical characteristics and outcomes of hospitalised patients with COVID-19 treated in Hubei (epicentre) and outside Hubei (non-epicentre): a nationwide analysis of China. Eur Respir J 2020; 55(6).
5. Murillo-Zamora E, Trujillo X, Huerta M, Rios-Silva M, Mendoza-Cano O. Male gender and kidney illness are associated with an increased risk of severe laboratory-confirmed coronavirus disease. BMC Infect Dis 2020; 20(1):674.
6. Bielicka JA, Duval X, Gobat N, Goossens H, Koopmans M, Taccone FS, et al. Monitoring approaches for health-care workers during the COVID-19 pandemic. Lancet Infect Dis 2020 Oct; 20(10):e2261–7.
7. Du RH, Liang LR, Yang CQ, Wang W, Cao TZ, Li M, et al. Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2: a prospective cohort study. Eur Respir J 2020; 55(5).
8. Santos MM, Lucena EES, Lima KC, Brito AAC, Bay MB, Bonfada D. Survival and predictors of deaths of patients hospitalised due to COVID-19 from a retrospective and multicentre cohort study in Brazil. Epidemiol Infect 2020; 148: e198.
9. Paranjpe I, Fuster V, Lala A, Russak AJ, Glicksberg BS, Levin MA, et al. Association of treatment dose anticoagulation with in-hospital survival among hospitalised patients with COVID-19. J Am Coll Cardiol 2020; 76(1):122–4.
10. Hernandez-Suarez CM, Verme P, Radyakin S, Murillo-Zamora E. COVID-19 outbreaks in refugee camps. A simulation study. medRxiv 2020; 2020.2010.2002.20204818.